Discovery and verification of extracellular microRNA biomarkers for diagnostic and prognostic assessment of preeclampsia at triage

We report on the identification of extracellular miRNA (ex-miRNA) biomarkers for early diagnosis and prognosis of preeclampsia (PE). Small RNA sequencing of maternal serum prospectively collected from participants undergoing evaluation for suspected PE revealed distinct patterns of ex-miRNA expressi...

Full description

Saved in:
Bibliographic Details
Published in:Science advances 2023-12, Vol.9 (51), p.eadg7545
Main Authors: Morey, Robert, Poling, Lara, Srinivasan, Srimeenakshi, Martinez-King, Carolina, Anyikam, Adanna, Zhang-Rutledge, Kathy, To, Cuong, Hakim, Abbas, Mochizuki, Marina, Verma, Kajal, Mason, Antoinette, Tran, Vy, Meads, Morgan, Lamale-Smith, Leah, Roeder, Hilary, Horii, Mariko, Ramos, Gladys A, DeHoff, Peter, Parast, Mana M, Pantham, Priyadarshini, Laurent, Louise C
Format: Article
Language:English
Subjects:
Biomarkers
Biomedicine and Life Sciences
Female
Health and Medicine
Humans
MicroRNAs - genetics
Pre-Eclampsia - diagnosis
Pre-Eclampsia - genetics
Pregnancy
Prognosis
SciAdv r-articles
Triage
Vascular Endothelial Growth Factor Receptor-1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report on the identification of extracellular miRNA (ex-miRNA) biomarkers for early diagnosis and prognosis of preeclampsia (PE). Small RNA sequencing of maternal serum prospectively collected from participants undergoing evaluation for suspected PE revealed distinct patterns of ex-miRNA expression among different categories of hypertensive disorders in pregnancy. Applying an iterative machine learning method identified three bivariate miRNA biomarkers ( , , and ) that, when applied serially, distinguished between PE cases of different severity and differentiated cases from controls with a sensitivity of 93%, specificity of 79%, positive predictive value (PPV) of 55%, and negative predictive value (NPV) of 89%. In a small independent validation cohort, these ex-miRNA biomarkers had a sensitivity of 91% and specificity of 57%. Combining these ex-miRNA biomarkers with the established sFlt1:PlGF protein biomarker ratio performed better than either set of biomarkers alone (sensitivity of 89.4%, specificity of 91.3%, PPV of 95.5%, and NPV of 80.8%).
ISSN:2375-2548
2375-2548
DOI:10.1126/SCIADV.ADG7545